Trial · NCT03545503
Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation
NCT03545503, Phase 4, Completed, South East Area Health Education Center, Wilmington, NC; results first posted 2021-11-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation. Trials, record NCT03545503. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03545503
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation
- NCT number
- NCT03545503
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 428 participants, actual
- Lead sponsor
- South East Area Health Education Center, Wilmington, NC
- Conditions
- Intubation Complication
- Interventions
- Etomidate, Ketamine
- First posted
- 2018-06-04
- Last updated
- 2021-11-26
- Results first posted
- 2021-11-26
- Limitations and caveats
Investigators nor clinicians were blinded to study drug. Resuscitation pre-RSI was not accounted for nor was the dosing for vascopressors. We could not control the slow administration of ketamine to decrease effects of hypotension due to rapid administration.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI | The hemodynamic response will be measured by assessing the change in vital signs between 15 minutes prior to administration and vitals up to 15 minutes after the administration of the study drug. | The primary outcome of this study is to determine the change in hemodynamic response comparing systolic blood pressure pre-versus post-administration of study drug. A significant hemodynamic response is defined as a decrease in systolic blood pressure of 20% or greater between the pre versus post administered study drug. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI | The hemodynamic response will be measured by assessing the change in vital signs between 15 minutes prior to administration and vitals up to 15 minutes after the administration of the study drug. | mmHg | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI | Etomidate | Pre-SBP | 138.04 | Standard Deviation 38.63 | mmHg |
| Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI | Ketamine | Pre-SBP | 132.39 | Standard Deviation 39.54 | mmHg |
| Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI | Etomidate | Post SBP 0-7 | 139.09 | Standard Deviation 44.52 | mmHg |
| Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI | Ketamine | Post SBP 0-7 | 130.09 | Standard Deviation 41.78 | mmHg |
| Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI | Etomidate | Post SBP 8-15 | 130.42 | Standard Deviation 42.19 | mmHg |
| Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI | Ketamine | Post SBP 8-15 | 120.80 | Standard Deviation 37.37 | mmHg |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Etomidate | 208 | |
| Overall Study | STARTED | Ketamine | 220 | |
| Overall Study | COMPLETED | Etomidate | 194 | |
| Overall Study | COMPLETED | Ketamine | 204 | |
| Overall Study | NOT COMPLETED | Etomidate | 14 | |
| Overall Study | NOT COMPLETED | Ketamine | 16 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Vascular disorders | Etomidate | 117 | 194 | |
| other | Hypertension | Vascular disorders | Ketamine | 111 | 204 | |
| other | Hypotension | Vascular disorders | Etomidate | 36 | 194 | |
| other | Hypotension | Vascular disorders | Ketamine | 53 | 204 | |
| serious | Hypertension | Vascular disorders | Etomidate | 0 | 194 | |
| serious | Hypertension | Vascular disorders | Ketamine | 1 | 204 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Etomidate | 0 | 194 |
| Total, all-cause mortality | Ketamine | 0 | 204 |
| Total, other adverse events | Etomidate | 117 | 194 |
| Total, other adverse events | Ketamine | 111 | 204 |
| Total, serious adverse events | Etomidate | 0 | 194 |
| Total, serious adverse events | Ketamine | 1 | 204 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39428602 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Etomidate vs Ketamine: deaths from any cause | Trial comparisons |
| Etomidate vs Ketamine: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03545503
GET https://conductscience.org/api/trials/v1/NCT03545503/registered